The First, Italian, Multicenter, Real-life Study with Erenumab in the Prevention of High Frequency Episodic and Chronic Migraine (2307) — Piero Barbanti (2020) | RDL Network
The First, Italian, Multicenter, Real-life Study with Erenumab in the Prevention of High Frequency Episodic and Chronic Migraine (2307)
Article 2020 en
Authors
PB
Piero Barbanti
CA
Cinzia Aurilia
SC
Sabina Cevoli
Abstract
1 min read
To report the first Italian, multicenter, real-life study with erenumab in the prevention of high frequency episodic (HFEM: 9–14 days/month) and chronic migraine (CM).
Discussion(0)
No comments yet. Be the first to comment.